Danaher Corporation (NYSE: DHR-PB) Stock Competitors & Peer Comparison
See DHR-PB's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DHR-PB and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $679.61 | +0.15% | 251.3B | 29.34 | $23.16 | +0.27% |
| DHR | $226.11 | -0.54% | 159B | 28.35 | $7.98 | +0.64% |
| NTRA | $414.52 | +0.67% | 59.4B | -314.03 | -$1.32 | N/A |
| A | $175.03 | -0.10% | 49.4B | 30.12 | $5.81 | +0.58% |
| IQV | $268.99 | -0.73% | 44.3B | 22.19 | $12.13 | N/A |
| WAT | $443.26 | +0.07% | 43.5B | 32.42 | $13.68 | N/A |
| IDXX | $533.44 | +0.83% | 42.1B | 37.51 | $14.22 | N/A |
| ILMN | $272.00 | +0.04% | 41.2B | 54.08 | $5.03 | N/A |
| MTD | $1,537.33 | -0.51% | 31.1B | 35.36 | $43.51 | N/A |
Stock Comparison
Thermo Fisher Scientific Inc. (NYSE: TMO)
DHR-PB vs TMO Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, TMO has a market cap of 251.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while TMO trades at $679.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas TMO's P/E ratio is 29.34. In terms of profitability, DHR-PB's ROE is +0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DHR-PB is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
DHR-PB vs DHR Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, DHR has a market cap of 159B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while DHR trades at $226.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DHR's P/E ratio is 28.35. In terms of profitability, DHR-PB's ROE is +0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
DHR-PB vs NTRA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NTRA has a market cap of 59.4B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NTRA trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NTRA's P/E ratio is -314.03. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, DHR-PB is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
DHR-PB vs A Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, A has a market cap of 49.4B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while A trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas A's P/E ratio is 30.12. In terms of profitability, DHR-PB's ROE is +0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, DHR-PB is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
DHR-PB vs IQV Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, IQV has a market cap of 44.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while IQV trades at $268.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IQV's P/E ratio is 22.19. In terms of profitability, DHR-PB's ROE is +0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, DHR-PB is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check IQV's competition here
Waters Corporation (NYSE: WAT)
DHR-PB vs WAT Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while WAT trades at $443.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WAT's P/E ratio is 32.42. In terms of profitability, DHR-PB's ROE is +0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, DHR-PB is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
DHR-PB vs IDXX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, IDXX has a market cap of 42.1B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while IDXX trades at $533.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IDXX's P/E ratio is 37.51. In terms of profitability, DHR-PB's ROE is +0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, DHR-PB is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
DHR-PB vs ILMN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ILMN has a market cap of 41.2B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ILMN trades at $272.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ILMN's P/E ratio is 54.08. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, DHR-PB is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
DHR-PB vs MTD Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MTD has a market cap of 31.1B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MTD trades at $1,537.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MTD's P/E ratio is 35.36. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, DHR-PB is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
DHR-PB vs DGX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, DGX has a market cap of 25.6B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while DGX trades at $231.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DGX's P/E ratio is 22.87. In terms of profitability, DHR-PB's ROE is +0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, DHR-PB is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
DHR-PB vs LH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while LH trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LH's P/E ratio is 18.33. In terms of profitability, DHR-PB's ROE is +0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, DHR-PB is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
DHR-PB vs GH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while GH trades at $177.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GH's P/E ratio is -50.93. In terms of profitability, DHR-PB's ROE is +0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, DHR-PB is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
DHR-PB vs EXAS Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas EXAS's P/E ratio is -95.37. In terms of profitability, DHR-PB's ROE is +0.08%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, DHR-PB is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
DHR-PB vs MEDP Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MEDP has a market cap of 17.4B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MEDP trades at $622.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEDP's P/E ratio is 36.47. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, DHR-PB is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
DHR-PB vs RVTY Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, RVTY has a market cap of 17B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while RVTY trades at $152.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RVTY's P/E ratio is 28.55. In terms of profitability, DHR-PB's ROE is +0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, DHR-PB is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
DHR-PB vs ILMNV Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ILMNV's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, DHR-PB is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
DHR-PB vs PKI Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PKI's P/E ratio is 41.45. In terms of profitability, DHR-PB's ROE is +0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, DHR-PB is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
DHR-PB vs CRL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CRL has a market cap of 14.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CRL trades at $295.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CRL's P/E ratio is 29.91. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, DHR-PB is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
DHR-PB vs ICLR Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ICLR trades at $170.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ICLR's P/E ratio is 13.89. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, DHR-PB is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
DHR-PB vs QGEN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while QGEN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas QGEN's P/E ratio is 18.34. In terms of profitability, DHR-PB's ROE is +0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, DHR-PB is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
DHR-PB vs GRAL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while GRAL trades at $136.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GRAL's P/E ratio is -14.01. In terms of profitability, DHR-PB's ROE is +0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, DHR-PB is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
DHR-PB vs RDNT Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while RDNT trades at $70.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas RDNT's P/E ratio is 153.59. In terms of profitability, DHR-PB's ROE is +0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, DHR-PB is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
DHR-PB vs BLLN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BLLN trades at $118.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BLLN's P/E ratio is 168.83. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
DHR-PB vs SHC Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while SHC trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SHC's P/E ratio is 19.38. In terms of profitability, DHR-PB's ROE is +0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, DHR-PB is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
DHR-PB vs SYNH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DHR-PB's ROE is +0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DHR-PB is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
DHR-PB vs VCYT Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while VCYT trades at $46.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas VCYT's P/E ratio is 23.04. In terms of profitability, DHR-PB's ROE is +0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, DHR-PB is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
DHR-PB vs CDNA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CDNA trades at $64.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CDNA's P/E ratio is 76.21. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, DHR-PB is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
DHR-PB vs OLK Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OLK's P/E ratio is -96.59. In terms of profitability, DHR-PB's ROE is +0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DHR-PB is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
DHR-PB vs WGS Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while WGS trades at $75.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WGS's P/E ratio is 210.53. In terms of profitability, DHR-PB's ROE is +0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, DHR-PB is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
DHR-PB vs PSNL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while PSNL trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PSNL's P/E ratio is -15.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, DHR-PB is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
DHR-PB vs OPK Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while OPK trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OPK's P/E ratio is -6.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, DHR-PB is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
DHR-PB vs CSTL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CSTL trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CSTL's P/E ratio is -52.85. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, DHR-PB is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
DHR-PB vs FLGT Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, FLGT has a market cap of 627.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while FLGT trades at $22.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas FLGT's P/E ratio is 2208.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, DHR-PB is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
DHR-PB vs GRALV Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GRALV's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, DHR-PB is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
DHR-PB vs NEO Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NEO has a market cap of 481.5M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NEO trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NEO's P/E ratio is 144.15. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, DHR-PB is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
DHR-PB vs CO Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CO's P/E ratio is 5.06. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, DHR-PB is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
DHR-PB vs MYGN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MYGN has a market cap of 399.5M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MYGN trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MYGN's P/E ratio is -32.54. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, DHR-PB is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
DHR-PB vs FLDM Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DHR-PB's ROE is +0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, DHR-PB is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
DHR-PB vs BDSX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BDSX has a market cap of 237.2M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BDSX trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BDSX's P/E ratio is -9.19. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, DHR-PB is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
DHR-PB vs XGN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while XGN trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas XGN's P/E ratio is -10.47. In terms of profitability, DHR-PB's ROE is +0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, DHR-PB is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
DHR-PB vs FRNM Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, FRNM has a market cap of 129.9M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while FRNM trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas FRNM's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to FRNM's ROE of N/A. Regarding short-term risk, DHR-PB is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
DHR-PB vs GTH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GTH's P/E ratio is -1.11. In terms of profitability, DHR-PB's ROE is +0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, DHR-PB is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
DHR-PB vs GENE Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas GENE's P/E ratio is -38.25. In terms of profitability, DHR-PB's ROE is +0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, DHR-PB is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
DHR-PB vs IMDX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas IMDX's P/E ratio is -2.27. In terms of profitability, DHR-PB's ROE is +0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, DHR-PB is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
DHR-PB vs SERA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SERA's P/E ratio is -3.15. In terms of profitability, DHR-PB's ROE is +0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, DHR-PB is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
DHR-PB vs PRPO Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, PRPO has a market cap of 42.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while PRPO trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PRPO's P/E ratio is -36.28. In terms of profitability, DHR-PB's ROE is +0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, DHR-PB is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
DHR-PB vs QUCY Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas QUCY's P/E ratio is -0.06. In terms of profitability, DHR-PB's ROE is +0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, DHR-PB is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
DHR-PB vs MDXH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MDXH has a market cap of 26.7M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MDXH's P/E ratio is -0.71. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, DHR-PB is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
DHR-PB vs AKU Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AKU's P/E ratio is -0.13. In terms of profitability, DHR-PB's ROE is +0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DHR-PB is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
DHR-PB vs BNR Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BNR has a market cap of 20M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BNR trades at $18.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BNR's P/E ratio is -21.77. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BNR's ROE of -0.13%. Regarding short-term risk, DHR-PB is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
DHR-PB vs CEMI Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DHR-PB is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
DHR-PB vs ENZ Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ENZ's P/E ratio is -2.24. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, DHR-PB is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
DHR-PB vs PMD Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PMD's P/E ratio is -5.24. In terms of profitability, DHR-PB's ROE is +0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, DHR-PB is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
DHR-PB vs ME Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ME's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ME's ROE of -42.03%. Regarding short-term risk, DHR-PB is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
DHR-PB vs MYNZ Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, DHR-PB is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
DHR-PB vs BIAFW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BIAFW has a market cap of 11.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIAFW's P/E ratio is 1.21. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, DHR-PB is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
DHR-PB vs CHEK Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CHEK's P/E ratio is -0.43. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, DHR-PB is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
DHR-PB vs CNTG Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DHR-PB is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
DHR-PB vs ADVB Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ADVB trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ADVB's P/E ratio is -57.45. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, DHR-PB is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
DHR-PB vs NDRA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NDRA trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NDRA's P/E ratio is -0.88. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, DHR-PB is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
DHR-PB vs APDN Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas APDN's P/E ratio is -0.10. In terms of profitability, DHR-PB's ROE is +0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, DHR-PB is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
DHR-PB vs NVTA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, DHR-PB is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
DHR-PB vs LMDXW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DHR-PB is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
DHR-PB vs LMDX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DHR-PB is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
DHR-PB vs DMTK Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, DHR-PB is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check DMTK's competition here
iSpecimen Inc. (NASDAQ: ISPC)
DHR-PB vs ISPC Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, ISPC has a market cap of 3M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while ISPC trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas ISPC's P/E ratio is -0.04. In terms of profitability, DHR-PB's ROE is +0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, DHR-PB is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
DHR-PB vs BIAF Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BIAF has a market cap of 2.9M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BIAF trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIAF's P/E ratio is -0.81. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, DHR-PB is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
DHR-PB vs NOTV Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NOTV's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, DHR-PB is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
DHR-PB vs SQL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SQL's P/E ratio is -0.40. In terms of profitability, DHR-PB's ROE is +0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, DHR-PB is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
DHR-PB vs AWH Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas AWH's P/E ratio is -0.09. In terms of profitability, DHR-PB's ROE is +0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, DHR-PB is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
DHR-PB vs HTGM Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DHR-PB's ROE is +0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DHR-PB is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
DHR-PB vs BIOC Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DHR-PB is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
DHR-PB vs SQLLW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, DHR-PB is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
DHR-PB vs WGSWW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, DHR-PB's ROE is +0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, DHR-PB is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
DHR-PB vs MEUSW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas MEUSW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, DHR-PB is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
DHR-PB vs PRXL Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas PRXL's P/E ratio is 42.97. In terms of profitability, DHR-PB's ROE is +0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, DHR-PB is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for DHR-PB.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
DHR-PB vs NDRAW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas NDRAW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, DHR-PB is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
DHR-PB vs CHEKZ Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, DHR-PB is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
DHR-PB vs OCDX Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas OCDX's P/E ratio is -42.28. In terms of profitability, DHR-PB's ROE is +0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, DHR-PB is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
DHR-PB vs DHR-PA Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, DHR-PB's ROE is +0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, DHR-PB is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
DHR-PB vs BNGOW Comparison September 2026
Danaher Corporation (NYSE: DHR-PB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHR-PB stands at 916.8B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, DHR-PB is priced at $1,261.26 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHR-PB currently has a P/E ratio of 146.01, whereas BNGOW's P/E ratio is N/A. In terms of profitability, DHR-PB's ROE is +0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, DHR-PB is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for DHR-PB.Check BNGOW's competition here